B.1.1.7 SARS CoV-2 Varyantına Bağlı COVID-19 Tanısıyla Takip Edilen Hastaların Değerlendirilmesi

Year 2022, Volume: 12 Issue: 3, 407 - 410, 20.09.2022

Şeyhmus Kavak Şafak Kaya Arzu Rahmanali Onur Gülnaz Kubat

https://doi.org/10.33631/sabd.1171198

Abstract

Amaç: COVID-19’un etkeni olan SARS-CoV-2’nin replikasyonu sırasında sayısız varyantlar ortaya çıkmaktadır. İki bin yirmi yılının Eylül ayında İngiltere’de ortaya çıkan B.1.1.7 (İngiltere) varyantı da bunlardan biridir. Bu çalışmada B.1.1.7 varyantına bağlı gelişen COVID-19 nedeniyle takip edilen hastaların verilerini gözden geçirmeyi amaçladık.
Gereç ve Yöntemler: Bu çalışma B.1.1.7 varyantının neden olduğu COVID-19 tanısıyla takip edilen toplam 50 hastanın verilerini içeren retrospektif bir çalışmadır. Hastalar yaş, cinsiyet, altta yatan hastalık, semptomlar ve laboratuar bulguları açısından incelendi.
Bulgular: Çalışmaya alınan 50 hastanın 20’si (%40) kadın ve yaş ortalaması 59,4±16,3 idi. Onbir (%22) hastada lökositoz, dört (%8) hastada lökopeni, 24 (%48) hastada lenfopeni, 42 (%84) hastada C reaktif protein artışı, 28 (%56) hastada ferritin yüksekliği, 32 (%64) hastada laktat dehidrogenaz yüksekliği, 16 (%32) hastada d-dimer yüksekliği mevcuttu. Hastaların 45 (%90)’inde toraks bilgisayarlı tomografide tutulum mevcuttu. Grup 1 (n=36) ve grup 2 (n=14) karşılaştırıldığında, iki grup arasında lökosit, d-dimer ve prokalsitonin düzeyleri arasında istatistiksel olarak anlamlı fark mevcuttu (p değerleri sırasıyla p˂0,000, p=0,001, p=0,001).
Sonuç: Sonuç olarak, B.1.1.7 varyantına sahip hastaları irdelediğimiz bu çalışmada ölen hastalarda lökosit, prokalsitonin ve d-dimer değerleri sağ kalan hastalara göre istatistiksel olarak anlamlı düzeyde daha yüksekti. Bu hastalardan elde ettiğimiz veriler varyant olmayan hastaların literatür verilerine benzerdi.

Keywords

B1.1.7 (İngiltere) varyantı, SARS CoV-2, COVID-19

Evaluation of Patients Followed Up with the Diagnosis of COVID-19 Caused by the B.1.1.7 SARS CoV-2 Variant

Abstract

Aim: During the replication of SARS-CoV-2, which is the causative agent of COVID-19, numerous variants emerge. The B.1.1.7 (England) variant, which appeared in England in September of the year 2000, is one of them. In this study, we aimed to review the data of patients followed up with a diagnosis of COVID-19 due to the B.1.1.7 variant.
Matherial and Methods: This study is a retrospective study containing the data of a total of 50 patients followed up with the diagnosis of COVID-19 caused by the B.1.1.7 variant. Patients were examined in terms of age, gender, underlying disease, symptoms and laboratory findings.
Results: Twenty (40%) of the 50 patients included in the study were female and the mean age was 59,4±16,3 years. Leukocytosis in 11 (22%) patients, leukopenia in 4 (8%) patients, lymphopenia in 24 (48%) patients, C-reactive protein increase in 42 (84%) patients, increased ferritin in 28 (56%) patients, and 32 (64%) patients lactate dehydrogenase elevation and d-dimer elevation were found in 16 (32%) patients. Forty-five (90%) patients had involvement in thorax computed tomography. When group 1 (n=36) and group 2 (n=14) were compared, there was a statistically significant difference between the leukocyte, d-dimer and procalcitonin levels between the two groups. (p˂0,000,p=0,001,p=0,001, respectively).
Conclusion: In conclusion, in this study, in which we examined patients with the B.1.1.7 variant, leukocyte, procalcitonin and d-dimer values were statistically significantly higher in patients who died than in patients who survived. The data we obtained from these patients were similar to the literature data of the patients without variants.

Keywords

B1.1.7 (England) variant, SARS CoV-2, COVID-19

References

• Ludwig S, Zarbock A. Coronaviruses and SARSCoV-2: A Brief Overview. Anesth Analg. 2020; 131(1): 93-6.
• Centers for Disease Control and Prevention-CDC (2021a). About Variants of the Virus that Causes COVID-19. https://www. cdc.gov/coronavirus/2019-ncov/transmission/variant.html Erişim Tarihi: 27.03.2021.
• Mavi D, İnkaya Ç. COVID-19: İmmün patogenez. Flora. 2020; 25(2): 121-31.
• Sümer Ş, UraL O, Aktuğ-Demir N, Çifci Ş, Türkseven B, Kılınçer A,ve ark. Selçuk Üniversitesi Tıp Fakültesi Hastanesi’nde izlenen COVID-19 olgularının klinik ve laboratuvar özellikleri. Klimik Derg. 2020; 33(2): 122-7.
• Zhang JJ, Dong X, Cao YY, Yuan YD, Yang YB, Yan YQ, et al. Clinical characteristics of 140 patients infected with SARS-CoV-2 in Wuhan, China. Allergy. 2020; 75(7): 1730-41.
• Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, et al. Clinical features of patients infec¬ted with 2019 novel coronavirus in Wuhan, China. Lancet. 2020; 395(10223): 497-506.
• Xu X, Yu C, Qu J, Zhang L, Jiang S, Huang D, et al. Imaging and clinical features of patients with 2019 novel coronavirus SARS-CoV-2. Eur J Nucl Med Mol Imaging. 2020; 47(5): 1275-80.
• Zhang ZL, Hou YL, Li DT, Li FZ. Laboratory findings of COVID-19: a systematic review and meta-analysis. Scand J Clin Lab Invest. 2020; 80(6): 441-7.
• Sönmezer MÇ, İnkaya AÇ. COVID-19: Viroloji, patogenez, klinik özellikler ve tedavi. Apraş Bilgen Ş, editör. COVID-19 Pandemisi ve Romatolojik Hastalıklar. 1. Baskı. Ankara: Türkiye Klinikleri; 2020. p.1-8.
• Ai T, Yang Z, Hou H, Zhan C, Chen C, Lv W, et al. Correlation of chest CT and RT-PCR testing in coronavirus disease 2019 (COVID-19) in China: A report of 1014 cases. Radiol. 2020; 296(2): 32-40.
• Dong D, Tang Z, Wang S, Hui H, Gong L, Lu Y, et al. The role of imaging in the detec¬tion and management of COVID-19: A review. IEEE Rev Biomed Eng. 2021; 14: 16-29. .